Oncotype DX Genomic Prostate Score® Test

Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Exact Sciences will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com
Where Insights
CONNECT
Histology • Biology • Endpoints • Outcomes

The Oncotype DX Genomic Prostate Score (GPS™) test is a genomic assay designed for men with low-, intermediate-, and high-risk localized prostate cancer to help guide treatment decisions at the time of diagnosis.1-23 The test analyzes prostate cancer gene activity to predict disease aggressiveness and provide clinically meaningful endpoints.

Connect insights across histology, biology, endpoints, and outcomes data for results that matter.

 

Reports that matter

With two tailored reports, the GPS test provides useful information for when active surveillance may be an appropriate decision for low- to intermediate-risk patients, as well as risk estimates to help inform your treatment decisions for higher-risk patients.1-23

The GPS test report helps facilitate discussions by consolidating key prostate cancer characteristics in a single document for ease of reference during management conversations.

Clinical evidence and endpoints matter

The Oncotype DX GPS test has been developed and studied in over 10,000 patients.1-12,14-23 The test provides crucial endpoints with actionable data to help address the needs of each patient.

Adverse Pathology: Predicts the risk of aggressive disease based on biopsy1,2

Metastasis and Prostate Cancer Death: Long-term endpoints predict future tumor behavior to ease patient concerns and offer confidence in clinical decisions3,14,15,23

The GPS assay is included in AUA, NCCN, ASCO, and EAU guidelines for risk-stratification.

Talking to your patients

It can be overwhelming for patients to remember all the information they are told during an office visit. During patient conversations, you can go over these points:

  • Resources are available that may be helpful in discussing prostate cancer and genomic testing
  • A genomic test measures the expression of genes within a sample of tumor tissue1
  • The Oncotype DX GPS test is a genomic test, and the results can help determine how aggressive the patient’s cancer is1

Watch this video to help explain GPS test results to your patient.

Personalized results matter

Graphic Low-risk vs. High-risk Patients

  • Easy-to-understand GPS test result ranging from 0 to 100 that corresponds to the biologic aggressiveness of the tumor

     

  • 17-gene signature, including 12 cancer-related genes representative of 4 key biological pathways and 5 reference genes

     

  • Predicts the likelihood of adverse pathology, prostate cancer death, and metastasis within 10 years1-3,15,23

     

The test is well suited for patients with localized prostate cancer, from clinically low-risk through high-risk.

Coverage and financial assistance

The GPS test is widely accessible, with minimal out-of-pocket costs for most patients.

†The Oncotype DX GPS assay is performed on claims with the unique proprietary laboratory analysis (PLA) code, 0047U.

Is your patient eligible?

The Oncotype DX Genomic Prostate Score assay is for patients who have:

  • Biopsy within 3 years
  • Not started treatment in low-risk setting (except for 5-alpha reductase inhibitors)
  • Localized prostate cancer*

*Excludes NCCN very-high-risk prostate cancer. Patients with NCCN very-low-, low-, intermediate-, and high-risk disease are eligible.

Order a Test

We make your ordering experience efficient. You can order a test through the physician portal, and we’ll help you every step of the way.